Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Bcr CRISPR/Cas9 KO Plasmid (m): sc-431007
- Target species: mouse
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- Bcr CRISPR/Cas9 Knockout (KO) Plasmid (m) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the Bcr genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: Bcr Antibody (B-12): sc-28375
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Bcr CRISPR/Cas9 KO Plasmid (m) | sc-431007 | 20 µg | $397.00 |
Overview
Mouse Bcr (breakpoint cluster region) encodes a multidomain signaling protein with serine/threonine kinase activity and a C-terminal Rho-family GTPase-activating (RhoGAP) domain, supporting regulation of cytoskeletal dynamics, adhesion, and cell migration. BCR participates in phosphorylation-dependent signal transduction and can modulate small GTPase pathways that influence proliferation and stress responses. In hematopoietic contexts, BCR is best known as a fusion partner with ABL1 in BCR–ABL-driven leukemogenic signaling, making its normal functions relevant for dissecting oncogenic pathway rewiring. In mouse models, perturbing Bcr supports mechanistic studies of kinase/GTPase crosstalk, actin remodeling, and context-specific growth control.
Bcr CRISPR/Cas9 KO Plasmid (m) is a pool of plasmids designed for targeted disruption of the Bcr gene in mouse cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the Bcr together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the Bcr open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish Bcr protein expression.
This CRISPR knockout system enables efficient generation of Bcr-deficient cell models for investigation of Bcr signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting Bcr exon(s) critical for Bcr function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple Bcr genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by Bcr CRISPR/Cas9 KO Plasmid (m) and Bcr CRISPR/Cas9 KO Plasmid (m2) target distinct sites within the Bcr locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by Bcr HDR Plasmid (m) and Bcr HDR Plasmid (m2) contain a puromycin resistance cassette and an RFP reporter flanked by Bcr homology arms to support homology-directed repair at defined Bcr target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.